These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24162638)

  • 1. Is public meningococcal C vaccination the preferred value for money at cost-neutral?
    Gravatt L
    N Z Med J; 2013 Oct; 126(1384):123-5. PubMed ID: 24162638
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal disease in New Zealand.
    Mills G; Bell A
    N Z Med J; 2013 Apr; 126(1373):10-1. PubMed ID: 23797072
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
    De Wals P; Nguyen VH; Erickson LJ; Guay M; Drapeau J; St-Laurent J
    Vaccine; 2004 Mar; 22(9-10):1233-40. PubMed ID: 15003652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pros and cons of vaccination against serogroup B meningococcal disease.
    Delgado Rodríguez M; Domínguez García Á
    Med Clin (Barc); 2018 Feb; 150(3):109-113. PubMed ID: 28992986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Northland emergency meningococcal C vaccination programme.
    Mills C; Penney L
    N Z Med J; 2013 Apr; 126(1373):30-9. PubMed ID: 23797074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 12. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry.
    Chung GS; Hutton DW
    PLoS One; 2020; 15(10):e0239926. PubMed ID: 33035260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Meningococcal vaccine. Editorial].
    Gendrel D; Cohen R
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S47-8. PubMed ID: 22883365
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; Erickson L
    Vaccine; 2002 Jun; 20(21-22):2840-4. PubMed ID: 12102036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The costs associated with the public health management of a cluster of meningococcal infection in England.
    Letouze D; Yao G; Clarke SC
    Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales.
    Trotter CL; Ramsay ME; Gray S; Fox A; Kaczmarski E
    Lancet Infect Dis; 2006 Oct; 6(10):616-7; author reply 617-8. PubMed ID: 17008169
    [No Abstract]   [Full Text] [Related]  

  • 20. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.